AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ACAD

Acadia: Q3 Earnings Snapshot

Acadia Pharmaceuticals (ACAD) reported Q3 earnings of $53.5M, or 31 cents per share, beating estimates. Revenue was $342.3M, also exceeding forecasts. The company expects full-year revenue between $1.26B and $1.3B. Shares are down 20% YTD and 2% over the past year.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Acadia: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ACADBullishMed
01

Why it matters

The earnings beat may attract short-term buying, but the modest guidance range suggests limited upside.

02

Market read

First-report earnings beat for a mid-cap biotech, offering a modest trading opportunity.

03

What to watch

Share price has fallen 20% YTD, indicating broader weakness that could dampen the rally.

Relevance 7/10Novelty 8/10Timing: post-market Wednesday

Background

Acadia Pharmaceuticals (NASDAQ: ACAD) is a specialty biopharma focused on central nervous system disorders.

Company-level read

Ticker impact

$ACADBullishHigh confidence
Context

Acadia Pharmaceuticals reported Q3 earnings beating estimates with $342.3M revenue and $0.31 EPS.

Expected impact

potential upside as market prices in earnings beat

Evidence & confidence

Revenue and EPS both exceeded Zacks consensus, suggesting stronger demand and profitability.

Market effects

Sector

Biotech sector may see modest lift from a mid-cap earnings beat.

Regional

US biotech investors could adjust positions after the surprise.

Global

Limited; impact confined to US-listed biotech space.

Counterpoint

What could challenge this read

Despite the beat, guidance remains modest; the stock may face profit-taking.

Key entities

  • Company
    Acadia Pharmaceuticals Inc.

    Biopharma reporting Q3 results.

Read at source← All news

StoryAcadia Pharmaceuticals posts Q3 2026 revenue of $342 million and raises full‑year outlook

Also covered by

4 outlets

Related articles

$ACADMedAI 8/10

What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call

ACADIA Pharmaceuticals (ACAD) reported Q3 earnings, highlighting a U.S. patent extension for DAYBUE until 2041. NUPLAZID sales grew 12% to $202M, with full-year guidance narrowed to $760M-$775M. The company expects $1.265B-$1.295B in 2026 revenue. R&D expenses fell to $76M, while SG&A rose to $159M. ACADIA remains confident in a NUPLAZID patent appeal and plans to refine its remlifanserin trial for Alzheimer's disease psychosis.

finance.yahoo.com
$ACADHighAI 8/10

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues - Third quarter DAYBUE ® GAAP net sales of $140 million, up 39% year-over-ye

SEC EDGAR 8-K
$NBIXMedAI 8/10

Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia

The Cambridgeshire and Peterborough NHS Foundation Trust launched AD-SMART, a UK trial testing multiple Alzheimer treatments simultaneously. Cognition Therapeutics aligned with the FDA on a phase 3 trial of zervimesine for dementia with Lewy bodies. Neurocrine Biosciences initiated a phase 2 study of NBI-'567 for Alzheimer disease. Acadia Pharmaceuticals reported phase 2 results for remlifanserin in Alzheimer disease psychosis.

psychiatrictimes.com